| David A Hinchman, MD | |
|
300 E Jefferson St, Suite 101, Boise, ID 83712-6246 | |
| (208) 322-1680 | |
| (208) 322-1695 |
| Full Name | David A Hinchman |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 32 Years |
| Location | 300 E Jefferson St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710914528 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | M8294 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Treasure Valley Hospital | Boise, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| High Desert Heart And Vascular | 7113389909 | 7 |
News Archive
Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal.
Researchers at the University of California, San Diego School of Medicine, led by Lucila Ohno-Machado, MD, PhD, chief of the Division of Biomedical Informatics in the Department of Medicine, have received two federal grants totaling more than $25 million to develop new ways to gather, analyze, use and share vast, ever-increasing amounts of biomedical information.
AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.
Researchers from Boston University School of Medicine (BUSM) have demonstrated that a recently discovered class of molecule called microRNA (miRNAs), regulate the gene expression changes in airway cells that occur with smoking and lung cancer.
› Verified 7 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal.
Researchers at the University of California, San Diego School of Medicine, led by Lucila Ohno-Machado, MD, PhD, chief of the Division of Biomedical Informatics in the Department of Medicine, have received two federal grants totaling more than $25 million to develop new ways to gather, analyze, use and share vast, ever-increasing amounts of biomedical information.
AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.
Researchers from Boston University School of Medicine (BUSM) have demonstrated that a recently discovered class of molecule called microRNA (miRNAs), regulate the gene expression changes in airway cells that occur with smoking and lung cancer.
› Verified 7 days ago
| Entity Name | High Desert Heart & Vascular |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508552043 PECOS PAC ID: 7113389909 Enrollment ID: O20230810002034 |
News Archive
Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal.
Researchers at the University of California, San Diego School of Medicine, led by Lucila Ohno-Machado, MD, PhD, chief of the Division of Biomedical Informatics in the Department of Medicine, have received two federal grants totaling more than $25 million to develop new ways to gather, analyze, use and share vast, ever-increasing amounts of biomedical information.
AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.
Researchers from Boston University School of Medicine (BUSM) have demonstrated that a recently discovered class of molecule called microRNA (miRNAs), regulate the gene expression changes in airway cells that occur with smoking and lung cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David A Hinchman, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 322-1680 | David A Hinchman, MD 300 E Jefferson St, Suite 101, Boise, ID 83712-6246 Ph: (208) 322-1680 |
News Archive
Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal.
Researchers at the University of California, San Diego School of Medicine, led by Lucila Ohno-Machado, MD, PhD, chief of the Division of Biomedical Informatics in the Department of Medicine, have received two federal grants totaling more than $25 million to develop new ways to gather, analyze, use and share vast, ever-increasing amounts of biomedical information.
AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.
Researchers from Boston University School of Medicine (BUSM) have demonstrated that a recently discovered class of molecule called microRNA (miRNAs), regulate the gene expression changes in airway cells that occur with smoking and lung cancer.
› Verified 7 days ago
Dr. Jennifer A Hofstra, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 757-446-8920 Fax: 757-446-5242 | |
Dr. James Robert Polk, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-3104 | |
Dr. Michael Frederic Krug, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 500 W. Fort St, # 111, Boise, ID 83702 Phone: 208-422-1000 Fax: 208-422-1319 | |
Derrel V Walker, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 208-367-7350 Fax: 208-367-3951 | |
Dr. Janat E. O'donnell, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 500 W. Fort St., # 111, Boise, ID 83702 Phone: 208-422-1325 Fax: 208-422-1319 | |
Carl L Durning, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 6094 W Emerald St, Boise, ID 83704 Phone: 208-367-6575 Fax: 208-367-6597 | |
Dr. Christopher J Goulet, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6259 W Emerald St, Boise, ID 83704 Phone: 208-489-1900 Fax: 208-375-5286 |